Bio­gen qui­et­ly whisks away its $544M au­toim­mune ri­val to Cel­gene

Bio­gen is sup­posed to be hunt­ing up new deals to fat­ten its late-stage pipeline. In­stead, the com­pa­ny used its quar­ter­ly num­bers re­view to­day to whisk one of its pro­grams out the back door with as lit­tle com­ment as pos­si­ble.

At the end of a ros­ter of pos­i­tive events in Q3, the big biotech not­ed: Bio­gen has dis­con­tin­ued de­vel­op­ment of amise­limod (MT-1303), which tar­gets the sphin­go­sine 1-phos­phate (S1P) re­cep­tor.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.